ALMIRALL, S.A. «...678910...» Page 8 out of 18 29/09/2022 08:02 ALMIRALL, S.A. Other relevant information Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc Register number: 18451 08/09/2022 14:16 ALMIRALL, S.A. On business and financial situation Almirall: Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Phase 3 Monotherapy Atopic Dermatitis Trials Register number: 18149 25/07/2022 07:23 ALMIRALL, S.A. On corporate governance Consejo de Administración Register number: 17512 25/07/2022 07:17 ALMIRALL, S.A. On business and financial situation Almirall announces that will webcast a conference to introduce and explain the results for the first half of 2022. Register number: 17511 25/07/2022 07:09 ALMIRALL, S.A. On business and financial situation Almirall files First Half results presentation for 2022 Register number: 17510 25/07/2022 07:05 ALMIRALL, S.A. Half-yearly financial reports and audit reports/limited audit review La sociedad remite información financiera del primer semestre de 2022 Register number: 17509 15/07/2022 11:44 ALMIRALL, S.A. Liquidity and counterparty agreements Operaciones del contrato de liquidez durante el segundo trimestre de 2022 Register number: 17399 08/06/2022 17:41 ALMIRALL, S.A. Total number of voting rights and capital La Sociedad comunica información relativa al dividendo flexible Register number: 16707 07/06/2022 06:03 ALMIRALL, S.A. On business and financial situation Eight out of Ten Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials Register number: 16634 03/06/2022 07:58 ALMIRALL, S.A. Other relevant information La Sociedad comunica información relativa al dividendo flexible Register number: 16592 Page 8 out of 18 «...678910...»
